1. Home
  2. ALLO
  3. ALLO News

Latest Allogene Therapeutics Inc. (ALLO) News on September 9, 2025

Allogene Therapeutics And 2 Other Promising Penny Stocks To Watch
ALLO

Simply Wall St.

2 months ago

Allogene Therapeutics And 2 Other Promising Penny Stocks To Watch

Why Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report?
ALLO

Zacks

3 months ago

Why Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report?

All You Need to Know About Allogene Therapeutics (ALLO) Rating Upgrade to Buy
ALLO

Zacks

3 months ago

All You Need to Know About Allogene Therapeutics (ALLO) Rating Upgrade to Buy

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
ALLO

GlobeNewswire

3 months ago

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
ALLO

GlobeNewswire

4 months ago

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel
ALLO

GlobeNewswire

4 months ago

Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel

Undervalued Opportunities: 3 Penny Stocks With Market Caps Above $30M
ALLO

Simply Wall St.

4 months ago

Undervalued Opportunities: 3 Penny Stocks With Market Caps Above $30M

Allogene (ALLO) Sinks 16% on Downgrade, Trial Delays
ALLO

GuruFocus.com

4 months ago

Allogene (ALLO) Sinks 16% on Downgrade, Trial Delays

Allogene Therapeutics (ALLO) Loses -31.94% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
ALLO

Zacks

4 months ago

Allogene Therapeutics (ALLO) Loses -31.94% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

ALLO

Thomson Reuters StreetEvents

4 months ago

Q1 2025 Allogene Therapeutics Inc Earnings Call

ALLO

MT Newswires

4 months ago

Oppenheimer Adjusts Allogene Therapeutics Price Target to $9 From $10, Maintains Outperform Rating

ALLO

MT Newswires

4 months ago

Truist Securities Adjusts Allogene Therapeutics Price Target to $10 From $14, Maintains Buy Rating

Allogene's Q1 Earnings In Line With Estimates, Sales Nil
ALLO

Zacks

4 months ago

Allogene's Q1 Earnings In Line With Estimates, Sales Nil

Allogene Therapeutics Inc (ALLO) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ...
ALLO

GuruFocus.com

4 months ago

Allogene Therapeutics Inc (ALLO) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ...

ALLO

Associated Press Finance

4 months ago

Allogene Therapeutics: Q1 Earnings Snapshot

Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update
ALLO

GlobeNewswire

4 months ago

Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update

Allogene Therapeutics Inc (ALLO) Q1 2025 Earnings Report Preview: What To Look For
ALLO

GuruFocus.com

4 months ago

Allogene Therapeutics Inc (ALLO) Q1 2025 Earnings Report Preview: What To Look For

Is Allogene Therapeutics, Inc. (ALLO) the Low Risk High Reward Stock Set to Triple by 2030?
ALLO

Insider Monkey

4 months ago

Is Allogene Therapeutics, Inc. (ALLO) the Low Risk High Reward Stock Set to Triple by 2030?

Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update
ALLO

GlobeNewswire

4 months ago

Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update

Allogene Therapeutics, Inc. (NASDAQ:ALLO) is a favorite amongst institutional investors who own 59%
ALLO

Simply Wall St.

4 months ago

Allogene Therapeutics, Inc. (NASDAQ:ALLO) is a favorite amongst institutional investors who own 59%

Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
ALLO

GlobeNewswire

5 months ago

Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug
ALLO

Zacks

5 months ago

FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug

ALLO

MT Newswires

5 months ago

Allogene Gets FDA Fast Track Designations for ALLO-329 in Autoimmune Diseases

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma
ALLO

GlobeNewswire

5 months ago

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

Allogene Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
ALLO

Simply Wall St.

6 months ago

Allogene Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Allogene Therapeutics Inc (ALLO) Q4 2024 Earnings Call Highlights: Financial Challenges Amid ...
ALLO

GuruFocus.com

6 months ago

Allogene Therapeutics Inc (ALLO) Q4 2024 Earnings Call Highlights: Financial Challenges Amid ...

Allogene's Q4 Loss Narrower Than Expected, Revenues Nil
ALLO

Zacks

6 months ago

Allogene's Q4 Loss Narrower Than Expected, Revenues Nil

ALLO

Associated Press Finance

6 months ago

Allogene Therapeutics: Q4 Earnings Snapshot

Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update
ALLO

GlobeNewswire

6 months ago

Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update
ALLO

GlobeNewswire

6 months ago

Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

Allogene Therapeutics Announces Participation in March Investor Conference
ALLO

GlobeNewswire

6 months ago

Allogene Therapeutics Announces Participation in March Investor Conference

Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia
ALLO

GlobeNewswire

6 months ago

Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia

Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology
ALLO

GlobeNewswire

7 months ago

Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology

Allogene Therapeutics Announces Participation in February Investor Conferences
ALLO

GlobeNewswire

7 months ago

Allogene Therapeutics Announces Participation in February Investor Conferences

FDA Clears Allogene's IND for CAR T Therapy in Autoimmune Diseases
ALLO

Zacks

7 months ago

FDA Clears Allogene's IND for CAR T Therapy in Autoimmune Diseases

Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer
ALLO

GlobeNewswire

7 months ago

Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer

ALLO

MT Newswires

7 months ago

Allogene Therapeutics Cleared to Start Phase 1 Testing of ALLO-329 Drug Candidate

Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases
ALLO

GlobeNewswire

7 months ago

Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases

3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025
ALLO

Zacks

8 months ago

3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025

Allogene Therapeutics (ALLO) Upgraded to Buy: What Does It Mean for the Stock?
ALLO

Zacks

8 months ago

Allogene Therapeutics (ALLO) Upgraded to Buy: What Does It Mean for the Stock?

3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying
ALLO

Zacks

9 months ago

3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying

Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
ALLO

GlobeNewswire

9 months ago

Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman
ALLO

GlobeNewswire

9 months ago

Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman

Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock?
ALLO

Zacks

9 months ago

Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock?

Allogene Therapeutics (ALLO) Upgraded to Buy: Here's Why
ALLO

Zacks

9 months ago

Allogene Therapeutics (ALLO) Upgraded to Buy: Here's Why

Allogene Therapeutics Announces Participation in December Investor Conferences
ALLO

GlobeNewswire

10 months ago

Allogene Therapeutics Announces Participation in December Investor Conferences

Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence
ALLO

GlobeNewswire

10 months ago

Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence

Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal
ALLO

Zacks

10 months ago

Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal

Allogene's Q3 Loss Narrower Than Expected, Sales Nil
ALLO

Zacks

10 months ago

Allogene's Q3 Loss Narrower Than Expected, Sales Nil

Allogene Therapeutics Inc (ALLO) Q3 2024 Earnings Call Highlights: Financial Resilience Amidst ...
ALLO

GuruFocus.com

10 months ago

Allogene Therapeutics Inc (ALLO) Q3 2024 Earnings Call Highlights: Financial Resilience Amidst ...

ALLO

Associated Press Finance

10 months ago

Allogene Therapeutics: Q3 Earnings Snapshot

Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update
ALLO

GlobeNewswire

10 months ago

Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update

CPRX Q3 Earnings & Revenues Beat Estimates, '24 View Raised, Stock Up
ALLO

Zacks

10 months ago

CPRX Q3 Earnings & Revenues Beat Estimates, '24 View Raised, Stock Up

Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS
ALLO

GlobeNewswire

10 months ago

Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS

Allogene Therapeutics Inc (ALLO) Q3 2024: Everything You Need To Know Ahead Of Earnings
ALLO

GuruFocus.com

10 months ago

Allogene Therapeutics Inc (ALLO) Q3 2024: Everything You Need To Know Ahead Of Earnings

Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting
ALLO

GlobeNewswire

10 months ago

Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting

Allogene Therapeutics Announces Participation in November Investor Conferences
ALLO

GlobeNewswire

10 months ago

Allogene Therapeutics Announces Participation in November Investor Conferences

Earnings Preview: ANI Pharmaceuticals (ANIP) Q3 Earnings Expected to Decline
ALLO

Zacks

10 months ago

Earnings Preview: ANI Pharmaceuticals (ANIP) Q3 Earnings Expected to Decline

Will Allogene Therapeutics (ALLO) Report Negative Earnings Next Week? What You Should Know
ALLO

Zacks

10 months ago

Will Allogene Therapeutics (ALLO) Report Negative Earnings Next Week? What You Should Know

Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update
ALLO

GlobeNewswire

10 months ago

Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update

ALLO

MT Newswires

10 months ago

Allogene's ALLO-316 Obtains FDA's RMAT Designation for Advanced Renal Cell Carcinoma

We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
ALLO

Simply Wall St.

10 months ago

We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully

Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T™ Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
ALLO

GlobeNewswire

10 months ago

Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T™ Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors
ALLO

GlobeNewswire

a year ago

Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors

Allogene Therapeutics, Inc. (ALLO): Among the Rising Penny Stocks to Invest In Now
ALLO

Insider Monkey

a year ago

Allogene Therapeutics, Inc. (ALLO): Among the Rising Penny Stocks to Invest In Now

Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference
ALLO

GlobeNewswire

a year ago

Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference

Allogene Therapeutics to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases, at the American College of Rheumatology (ACR) Convergence
ALLO

GlobeNewswire

a year ago

Allogene Therapeutics to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases, at the American College of Rheumatology (ACR) Convergence

IGM Biosciences (IGMS) Surges 11.6%: Is This an Indication of Further Gains?
ALLO

Zacks

a year ago

IGM Biosciences (IGMS) Surges 11.6%: Is This an Indication of Further Gains?

Allogene Therapeutics, Inc. (ALLO): Short Seller Sentiment is Bearish on This Cancer Stock
ALLO

Insider Monkey

a year ago

Allogene Therapeutics, Inc. (ALLO): Short Seller Sentiment is Bearish on This Cancer Stock

Allogene Therapeutics (ALLO) Up 6.4% Since Last Earnings Report: Can It Continue?
ALLO

Zacks

a year ago

Allogene Therapeutics (ALLO) Up 6.4% Since Last Earnings Report: Can It Continue?

Allogene Therapeutics Second Quarter 2024 Earnings: US$0.35 loss per share (vs US$0.53 loss in 2Q 2023)
ALLO

Simply Wall St.

a year ago

Allogene Therapeutics Second Quarter 2024 Earnings: US$0.35 loss per share (vs US$0.53 loss in 2Q 2023)

Allogene (ALLO) Posts Narrower Than Expected Loss in Q2
ALLO

Zacks

a year ago

Allogene (ALLO) Posts Narrower Than Expected Loss in Q2

ALLO

MT Newswires

a year ago

Truist Adjusts Allogene Therapeutics' PT to $14 From $17, Keeps Buy Rating

ALLO

MT Newswires

a year ago

Oppenheimer Adjusts Allogene Therapeutics Price Target to $11 From $13, Maintains Outperform Rating

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
ALLO

GlobeNewswire

a year ago

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

ALLO

Associated Press Finance

a year ago

Allogene Therapeutics: Q2 Earnings Snapshot

Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update
ALLO

GlobeNewswire

a year ago

Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update

Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update
ALLO

GlobeNewswire

a year ago

Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update

Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)
ALLO

GlobeNewswire

a year ago

Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)

With 56% institutional ownership, Allogene Therapeutics, Inc. (NASDAQ:ALLO) is a favorite amongst the big guns
ALLO

Simply Wall St.

a year ago

With 56% institutional ownership, Allogene Therapeutics, Inc. (NASDAQ:ALLO) is a favorite amongst the big guns

Allogene Therapeutics, Inc. (ALLO): Are Analysts Bullish About the Potential of This Small-Cap Stock?
ALLO

Insider Monkey

a year ago

Allogene Therapeutics, Inc. (ALLO): Are Analysts Bullish About the Potential of This Small-Cap Stock?

Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse
ALLO

GlobeNewswire

a year ago

Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse

Allogene Therapeutics (ALLO) Down 13.9% Since Last Earnings Report: Can It Rebound?
ALLO

Zacks

a year ago

Allogene Therapeutics (ALLO) Down 13.9% Since Last Earnings Report: Can It Rebound?

ALLO

MT Newswires

a year ago

Piper Sandler Starts Allogene Therapeutics With Overweight Rating, $11 Price Target

Insiders Pour Millions Into These 2 ‘Strong Buy’ Stocks
ALLO

TipRanks

a year ago

Insiders Pour Millions Into These 2 ‘Strong Buy’ Stocks

Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit
ALLO

GlobeNewswire

a year ago

Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit

ALLO

MT Newswires

a year ago

Oppenheimer Trims Allogene Therapeutics Price Target to $13 From $14, Maintains Outperform Rating

ALLO

MT Newswires

a year ago

HC Wainwright Adjusts Price Target on Allogene Therapeutics to $9 From $10, Keeps Buy Rating

Allogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag
ALLO

Zacks

a year ago

Allogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag

ALLO

MT Newswires

a year ago

Stifel Adjusts Price Target on Allogene Therapeutics to $4.60 From $4.40, Keeps Hold Rating

ALLO

MT Newswires

a year ago

B. Riley Adjusts Price Target on Allogene Therapeutics to $7 From $10, Keeps Buy Rating

ALLO

GuruFocus.com

a year ago

Allogene Therapeutics Inc (ALLO) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...

ALLO

MT Newswires

a year ago

Allogene Therapeutics Prices $110 Million Offering

Allogene Therapeutics (ALLO) Reports Q1 Loss, Lags Revenue Estimates
ALLO

Zacks

a year ago

Allogene Therapeutics (ALLO) Reports Q1 Loss, Lags Revenue Estimates

Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
ALLO

GlobeNewswire

a year ago

Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock

ALLO

Associated Press Finance

a year ago

Allogene Therapeutics: Q1 Earnings Snapshot

ALLO

MT Newswires

a year ago

Allogene Therapeutics Q1 Loss Narrows, Revenue Declines

Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
ALLO

GlobeNewswire

a year ago

Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update

CollPlant Biotechnologies (CLGN) Soars 8.2%: Is Further Upside Left in the Stock?
ALLO

Zacks

a year ago

CollPlant Biotechnologies (CLGN) Soars 8.2%: Is Further Upside Left in the Stock?

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
ALLO

GlobeNewswire

a year ago

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

Share on Social Networks: